ARIAD PHARMACEUTICALS $17.79

down -0.03


18/6/2013 04:18 PM  |  NASDAQ : ARIA  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
Get Trend Analysis Icon Get ARIA Trend Analysis - it has underperformed the S&P 500 by 24%

Partner Headlines

  1. UPDATE: Stifel Nicolaus Cuts PT to $26 on Ariad Pharmaceuticals on ...

    Benzinga

  2. ARIAD Announces Completion of Public Offering

    Benzinga

  3. ARIAD, UK National Cancer Research Institute to Collaborate on ...

    Benzinga

  4. Ariad Pharmaceuticals (ARIA) Executive VP, CFO Edward M Fitzgerald ...

    GuruFocus

  5. UPDATE: Maxim Group Cuts PT to $24 on ARIAD Pharmaceuticals; Label ...

    Benzinga

  6. UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on ...

    Benzinga

  7. Citigroup Reiterates Buy Rating, $31 PT on Ariad Pharmaceuticals

    Benzinga

  8. ARIAD Confirms Accelerated FDA Approval of Iclusig

    Benzinga

  9. ARIAD Offers 12-Mo. Data from Pivotal PACE Trial of Ponatinib

    Benzinga

  10. ARIAD Reports Positive 12-Month Data from Pivotal PACE Trial of ...

    Benzinga

  11. UPDATE: Dawson James Initiates Coverage on Ariad Pharmaceuticals ...

    Benzinga

  12. ARIAD Pharma Publishes Phase 1 Trial Results of Ponatinib in NEJoM

    Benzinga

  13. ARIAD , Foundation Medicine Announce Collaboration on AP26113 Study

    Benzinga

  14. ARIAD Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus

  15. ARIAD Announces FDA Acceptance of NDA Filing for Ponatinib

    Benzinga

  16. UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on ...

    Benzinga

  17. Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)

    Benzinga

  18. Highs & Lows: Ariad Pharmaceuticals, IBM, LDK Solar, and Visa

    By SchaeffersResearch

  19. Maxim Group Reiterates Buy Rating, $28 PT on Ariad Pharmaceuticals

    Benzinga

  20. UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, ...

    Benzinga

  21. Ariad's Partner Withdraws Its Diagnostic Test; Here's Why That ...

    YCharts

  22. MolecularMD Withdraws Premarketing Approval Application from FDA ...

    Benzinga

  23. UPDATE: Bank of America Upgrades Ariad Pharmaceuticals to Buy on ...

    Benzinga

  24. Novartis, Nationstar Mortgage Holdings Among Stocks Setting ...

    FOXBusiness

  25. ARIAD Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus

  26. UPDATE: Maxim Group Reiterates Buy Rating, Raises PT on Ariad ...

    Benzinga

  27. Ariad Announces Submission of New Drug Application for Ponatinib ...

    Benzinga

  28. ARIAD Announces Initiation of Randomized Phase 3 Trial of ...

    Benzinga

  29. ARIAD Pharmaceuticals Inc. (ARIA) Executive VP, CFO Edward M ...

    GuruFocus

  30. Ariad Pharmaceuticals (ARIA) Trading Up 2.6%, Sees Over 3x Average ...

    At Market Intelligence Center

  31. Option Alert: Ariad Pharmaceuticals August 12 Put; Block Trade: ...

    Benzinga

  32. UPDATE: Jefferies Raises PT to $18 on ARIAD Pharmaceuticals; ...

    Benzinga

  33. Ariad Pharmaceuticals (ARIA) Up 4.8% After Negative Drug Review, ...

    At Market Intelligence Center

  34. Bank of America: Closer Look at Ariad Pharmaceuticals' Inhibitor ...

    at Benzinga

  35. ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K)

    at GuruFocus

  36. UPDATE: Oppenheimer Ups PT to $20 on Ariad Pharmaceuticals

    at Benzinga

  37. Rodman & Renshaw Maintains Market Perform, $18 PT

    at Benzinga

  38. Notable Put Options Activity in ARIAD Pharmaceuticals

    at Benzinga

  39. Ariad Pharmaceuticals (ARIA) Sees Heavy Put Volume as Stock Trades ...

    At Market Intelligence Center

  40. Benzinga's Volume Gainers

    at Benzinga

  41. Notable Put Options Activity on ARIAD Pharmaceuticals

    at Benzinga

  42. Best Biotech Stocks of 2011

    at Benzinga

  43. Rodman & Renshaw Raises PT on ARIAD Pharma to $18

    at Benzinga

  44. Notable Put Options Activity in ARIAD Pharmaceuticals

    at Benzinga

  45. ARIAD Announces Underwriters' Exercise of Over-Allotment Option

    at Benzinga

  46. Ariad Pharmaceuticals (ARIA) Gains 5.4% after Pricing Offering

    At Market Intelligence Center

  47. ARIAD Announces Proposed Public Offering of Common Stock

    at Benzinga

  48. Bank of America Maintains Neutral, $14 PT on Ariad Pharmaceuticals

    at Benzinga

  49. Benzinga's Top Pre-Market Gainers

    at Benzinga

  50. Jefferies Maintains Buy Rating on Ariad Pharma

    at Benzinga

  51. J.P. Morgan Maintains Overweight Rating on Ariad Pharmaceuticals

    at Benzinga
People viewing ARIA also viewed: , , , , , ,
Marketplace
Trading Center